Interstitial Lung Disease Caused by Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

被引：0
|
作者：
del Castillo-Acuna, Rocio [1 ]
Serradilla, Ana [2 ,3 ]
Lopez-Campos, Fernando [4 ]
Counago, Felipe [5 ,6 ]
机构：
[1] Hosp Univ Punta Europa, Dept Radiat Oncol, Algeciras, Spain
[2] Complejo Hosp Jaen, Dept Radiat Oncol, Jaen, Spain
[3] Hosp Univ Ramon & Cajal, Dept Radiat Oncol, Madrid, Spain
[4] Hosp San Francisco Asis, Dept Radiat Oncol GenesisCare, Madrid, Spain
[5] Hosp Vithas La Milagrosa, Dept Radiat Oncol GenesisCare, Madrid, Spain
[6] GenesisCare Espana, Nacl Clin & Invest, Madrid, Spain
来源：
ARCHIVOS DE BRONCONEUMOLOGIA | 2024年 / 60卷 / 08期
关键词：
D O I：
10.1016/j.arbres.2024.04.009
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：537 / 538
页数：2
相关论文
共 50 条
  • [31] Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer
    MacVicar, Gary R.
    Hussain, Maha H.
    CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) : 252 - 260
  • [32] Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease
    Ozguroglu, Mustafa
    Chowdhury, Simon
    Bjartell, Anders
    Uemura, Hirotsugu
    Chung, Byung Ha
    Agarwal, Neeraj
    Merseburger, Axel Stuart
    Soto, Alvaro Juarez
    Lopez-Gitlitz, Angela
    Bhaumik, Amitabha
    Larsen, Julie S.
    McCarthy, Sharon Anne
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2018, 199 (01): : 26 - 28
  • [34] First-line Therapy for Metastatic Castration-sensitive Prostate Cancer
    Lau, Y. H.
    Wan, L. Y.
    Lam, M. H. C.
    HONG KONG JOURNAL OF RADIOLOGY, 2022, 25 (03): : 244 - 245
  • [35] Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer
    Dandapani, Savita V.
    Wong, Jeffrey
    Twardowski, Przemyslaw
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (07) : 490 - 496
  • [36] Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer
    Grisay, Guillaume
    Lavaud, Pernelle
    Fizazi, Karim
    CURRENT ONCOLOGY REPORTS, 2024, 26 (05) : 488 - 495
  • [37] Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer
    Miyake, Hideaki
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Tamura, Keita
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    ANTICANCER RESEARCH, 2019, 39 (03) : 1391 - 1396
  • [38] COST-EFFECTIVENESS OF ABIRATERONE, ENZALUTAMIDE, AND APALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): A PARTITIONED-SURVIVAL MODEL
    Katta, A.
    Hansen, R. N.
    VALUE IN HEALTH, 2023, 26 (06) : S68 - S68
  • [39] Re: Abiraterone plus Prednisone in Metastatic, Castration-sensitive Prostate Cancer
    Faiena, Izak
    Salmasi, Amirali
    Pantuck, Allan J.
    Drakaki, Alexandra
    EUROPEAN UROLOGY, 2018, 73 (06) : 981 - 981
  • [40] Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer
    Struss, Werner J.
    Black, Peter C.
    UROLOGY, 2017, 109 : 1 - 2
12345